文献速递其他结缔组织病

辅助血浆置换对anti-SRP抗体阳性特发性炎性肌病的获益:真实世界研究

Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该真实世界研究纳入53例anti-SRP抗体阳性肌病患者,比较辅助血浆置换(PE)与标准治疗的疗效。PE组基线病情更重,但4周时六项核心指标改善更显著,中位随访15个月后经IPW分析预后更优。多因素Cox回归显示PE治疗与间质性肺病为长期预后的独立预测因素。

要点

  • 辅助PE组4周时六项核心指标改善均显著优于标准治疗组(均P<0.001)。
  • 中位随访15个月,IPW分析显示PE组复合终点(全因死亡和复发)预后显著更优(P=0.029)。
  • 多因素Cox回归中PE治疗[HR 0.14(0.03-0.57),P=0.006]与间质性肺病[HR 4.82(1.22-19.12),P=0.025]为独立预测因素。

核心结论

  • 辅助血浆置换可为anti-SRP抗体阳性特发性炎性肌病患者提供快速缓解和持续获益。

研究设计与样本

  • 真实世界研究连续纳入并随访anti-SRP抗体阳性肌病患者,比较辅助血浆置换联合标准治疗与标准治疗的疗效。
  • 采用双向方差分析比较两组治疗前后肌炎疾病活动度变化,经倾向评分匹配和逆概率加权后以Kaplan-Meier法比较全因死亡和复发的复合终点,并用Cox回归筛选长期预后因素。
  • 共纳入53例患者,其中35例接受标准治疗,18例接受辅助血浆置换治疗。

主要发现

  • 血浆置换组基线肌肉无力更严重(P=0.027)、anti-SRP抗体滴度更高(P=0.001)、肌酸激酶水平更高(P<0.001)且糖皮质激素用量更大(P=0.038)。
  • 治疗4周随访时两组均获显著缓解,六项核心指标均显著改善,且血浆置换组六项核心指标变化更显著(均P<0.001)。
  • 中位随访15个月期间26例患者达到复合终点,经逆概率加权分析血浆置换组预后显著更优(P=0.029)。
  • 多因素Cox回归分析显示,血浆置换治疗[风险比:0.14(0.03-0.57),P=0.006]和间质性肺病[风险比:4.82(1.22-19.12),P=0.025]为长期预后的独立预测因素。

临床怎么用

  • 对于anti-SRP抗体阳性特发性炎性肌病患者,在标准治疗基础上辅助血浆置换可能促进快速缓解并改善长期预后。
  • 间质性肺病是长期预后不良的独立预测因素,此类患者需加强监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to compare the efficacy of adjunct plasma exchange (PE) therapy with standard therapy in idiopathic inflammatory myopathy (IIM) with anti-signal recognition particle (SRP) antibodies. METHODS: Anti-SRP-positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan-Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors. RESULTS: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03-0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22-19.12), P = 0.025] turned out to be independent predictors for long-term prognosis. CONCLUSION: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shi Y, Guo J, Sun J, et al. Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study. Rheumatology (Oxford). 2026. PMID: 42036842. doi:10.1093/rheumatology/keag225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。